Chester County News and Community Website
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced that it received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration (FDA). …
Verrica Pharmaceuticals Gains FDA Alignment for YCANTH’s Phase 3 Clinical Development Plan Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a Pennsylvania-based biotechnology company, has announced new preclinical data on two of its drug candidates, istaroxime and CVie-216. The drugs have shown …
Windtree’s Innovative Drugs Show Promising Reductions in Ventricular Arrhythmias Read More
KING OF PRUSSIA, PA — CSL (ASX: CSL; USOTC: CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) have made a significant leap forward in the fight against COVID-19, as revealed by a …
CSL and Arcturus Therapeutics’ Novel COVID-19 Booster Outperforms Conventional Vaccine in Phase 3 Study Read More
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has made a significant step forward in its quest to secure regulatory approval for Intravenous (IV) Ketamine as a treatment for acute …
NRx Pharmaceuticals Advances Efforts to Secure FDA Approval for IV Ketamine in Treating Suicidal Depression Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reached a critical milestone in its quest to revolutionize hypertension treatment. The company recently announced that the first subject in the …
Mineralys Therapeutics Advances in Its Pivotal Hypertension Trial with First Dose of Lorundrostat Administered Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, recently announced that it has received alignment from the U.S. Food and Drug Administration (FDA) on the design of a …
Ocugen Gains FDA Alignment for Phase 3 Trial of Retinitis Pigmentosa Treatment Read More
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG), a gene therapy company, recently unveiled initial safety and biomarker data from the first phase of its upliFT-D clinical trial. The trial …
Passage Bio’s Gene Therapy Shows Promise in Early-Stage Trials for Frontotemporal Dementia Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is making strategic moves, announcing several updates this week including promising trial results, a shift in drug development focus, and a significant …
Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital Read More WARRINGTON, PA — Windtree Therapeutics, Inc., a Pennsylvania-based biotech firm, this week launched a Phase 2 extension study of istaroxime, a novel therapy designed for early cardiogenic shock treatment, marking …
Windtree Therapeutics Advances Cardiogenic Shock Treatment, Begins Phase 2 SEISMiC Extension Study Read More
WILMINGTON, DE — Cairn Therapeutics, a biotechnology firm, has announced the formation of its new management team and the election of a new Board of Directors.
Cairn Therapeutics Announces New Management Team and Board of Directors, Gears for Phase I Trial Read More